Abstract
MK-434 is a new 5α-reductase inhibitor. A sensitive and specific assay based on combined liquid chromatography—mass spectrometry (LC—MS) has been developed for the determination of this compound in plasma. The analyte was isolated from plasma by solid-phase extraction on a C 18 cartridge. A related substance, L-654,066, was used as the internal standard. Extracts were separated on a 5-cm C 18-reversed-phase high performance liquid chromatography column interfaced via the heated nebulizer probe to a corona discharge chemical ionization source. The mass spectrometer was operated in the positive ion MS—MS mode. The method had sufficient sensitivity, precision, accuracy, and selectivity for the analysis of clinical samples containing MK-434 and its two principal metabolites at concentrations in the range 0.5–50 ng ml −1. The chromatographic run time was <5 min.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Journal of Pharmaceutical and Biomedical Analysis
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
